Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2024-11-01 DOI:10.1016/j.jtho.2024.08.017

Maria Carmela Piccirillo MD , Quincy Chu MD , Penelope Bradbury MD , Wei Tu PhD , Courtney H. Coschi MD, PhD , Federica Grosso MD , Marie Florescu MD , Manlio Mencoboni MD , John R. Goffin MD , Maria Pagano MD , Fortunato Ciardiello MD, PhD , Fabiana Letizia Cecere MD , Mark Vincent MD , Roberto Ferrara MD , David E. Dawe MD, MSc , Desiree Hao MD , Christopher W. Lee MD , Alessandro Morabito MD , Cesare Gridelli MD , Luigi Cavanna MD , Scott A. Laurie MD

引用次数: 0

查看原文本刊更多论文

对 "简要报告 "的勘误：加拿大癌症试验组 IND.227：pembrolizumab 用于晚期恶性胸膜间皮瘤患者的 II 期随机研究（NCT02784171）。[胸腔肿瘤学杂志》第 18 卷第 6 期：813-819]"。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.